FAQ on Calidi Biotherapeutics Inc.'s Leadership Change and Clinical Growth
Summary
Who has been appointed as the new CEO of Calidi Biotherapeutics Inc.?
Eric Poma, Ph.D., has been appointed as the new Chief Executive Officer of Calidi Biotherapeutics Inc., effective April 22.
What experience does Eric Poma bring to Calidi Biotherapeutics Inc.?
Eric Poma brings over 30 years of biotech leadership experience, including significant roles at Molecular Templates where he raised over $250 million and secured strategic partnerships with major pharmaceutical companies.
What is Calidi Biotherapeutics Inc.’s focus under its new CEO?
Under its new CEO, Calidi Biotherapeutics Inc. focuses on advancing its systemic virotherapy platform and preparing for a dose-escalation trial of CLD-201 in solid tumors, aiming to transition into later-stage clinical development.
Where is Calidi Biotherapeutics Inc. headquartered?
Calidi Biotherapeutics Inc. is headquartered in San Diego, California.
What technology does Calidi Biotherapeutics Inc. specialize in?
Calidi Biotherapeutics Inc. specializes in proprietary stem cell-based platforms that utilize allogeneic stem cells to carry payloads of oncolytic viruses for treating various oncology indications, including high-grade gliomas and solid tumors.
How can investors stay updated on Calidi Biotherapeutics Inc.?
Investors can stay updated on Calidi Biotherapeutics Inc. by visiting the company’s newsroom at https://ibn.fm/CLDI.
What is the significance of Calidi Biotherapeutics Inc.’s leadership change?
The leadership change signifies Calidi Biotherapeutics Inc.’s strategic move to leverage Eric Poma’s extensive experience in biotech leadership and fundraising to advance its clinical development and therapeutic platforms.
What are the potential benefits of Calidi Biotherapeutics Inc.’s technology?
Calidi Biotherapeutics Inc.’s technology is designed to protect, amplify, and potentiate oncolytic viruses, leading to enhanced efficacy and improved patient safety in treating or even preventing metastatic disease.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 120414